Thomas Hadley

Utility Therapeutics Ltd. is a British company that has exclusive US commercial rights to two European-approved antibiotics, mecillinam and an oral prodrug of mecillinam, for the treatment of urinary tract infections (UTI). The private company is based in Altrincham, UK and was founded in 2018 by Rasmus Toft-Kehler, Morten Otto Alexander Sommer, Peter Aksel Villadsen. Mecillinam is being developed as a first-line therapy for complicated UTI in the hospital setting, while the oral prodrug is being developed for uncomplicated UTI. The company has received the FDA's Qualified Infectious Disease Product (QIDP) designation for the treatment of UTI. Utility Therapeutics is committed to developing antibiotics that meet urgent treatment needs for multi-drug resistant infections.

Bausch & Lomb, Inc. develops, manufactures, and markets eye health products. It offers over-the-counter supplements, eye care products, ophthalmic pharmaceuticals, contact lenses, lens care, ophthalmic surgical devices, and instruments. The company was founded by John Jacob Bausch and Henry Lomb in 1853 and is headquartered in Rochester, NY.

Horizon Pharmaceuticals, Inc. is a pharmaceutical company that specializes in the development, manufacture, and lifecycle management of blow-fill-seal (BFS) technology and products for the pharmaceutical, medical device, diagnostic, and clinical industries. The private company is based in West Palm Beach, FL and operates two segments: blow-fill-seal drug discovery and development and blow-fill-seal manufacturing, including in-house mold fabrication. The company is a leader in custom BFS aseptic manufacturing and have the capabilities to complete projects at any stage of the development cycle. The company also holds a state license for the manufacture of pharmaceutical drugs (OTC and prescription) and medical devices.